Funding for this research was provided by:
National Health and Medical Research Council (APP1114016, APP1108254, APP1136067)
University of New South Wales
Cancer Institute NSW (2018/ECF013)
Received: 30 August 2021
Accepted: 16 December 2021
First Online: 12 January 2022
: Ethics approval was not required for this study.
: I.W.D. manages a fee-for-service nanopore sequencing facility at the Garvan Institute of Medical Research that is a customer of Oxford Nanopore Technologies but has no further financial relationship. The other authors declare that they have no competing interests.